A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer

ESSIGHT-HJG-ES502-01 is a dose-escalation study of ES502 in patients with advanced pancreatic cancer. The study will enroll patients with advanced, RAS G12V positive pancreatic cancer who have no effective treatment options available (HLA genotyping required).

Trial Details

NCT ID

NCT07649928

Phase

EARLY_PHASE1

Sponsor

Ruijin Hospital

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

ES502 Injection

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

To be enrolled in this study, participants must meet all of the following inclusion criteria:
Age ≥18 years, regardless of gender;
Available fresh or archived tumor tissue samples (within the past 5 years) for testing at screening;
Individuals with histologically or cytologically confirmed advanced solid tumors for whom no standard therapy exists, who are refractory to standar…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →